ClinicalTrials.gg
CompletedNCT00779064Updated Dec 25, 2014

BAY59-7939, Japanese Phase II in Atrial FibrillationTrial Status

A Phase 2 interventional study of Rivaroxaban (BAY59-7939) and Rivaroxaban (BAY59-7939) in Atrial Fibrillation, sponsored by Bayer. Completed at 12 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2014-12-25.

Sponsored by Bayer · Phase 2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
36
Allocation
Non-randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 45 studies testing rivaroxaban in Atrial Fibrillation — 8 open to participants now, 9 under way, none of them phase 3. Rivaroxaban · Atrial Fibrillation.

Enrollment
42nd of 45
36 · median 150
Started
2004
the only one that year
Phase 2
3 of 45
none open now
Registered
3rd of 45
by date
Lead sponsor
8 of 45
Bayer

Among the 45 studies testing rivaroxaban in Atrial Fibrillation, this one is the 42nd largest by enrollment, is the only one that started in 2004, is one of 3 in phase 2, and was the 3rd registered.

Atrial Fibrillation

4,011 studies on the registry are indexed under Atrial Fibrillation; 961 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

8 of the 45 studies testing rivaroxaban in Atrial Fibrillation are open now, in 4 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About rivaroxaban

Rivaroxaban: first FDA approval 2011 (XARELTO), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 611 Atrial Fibrillation studies recruiting now, 407 (67%) set no upper age limit and 43 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 45 studies testing rivaroxaban in Atrial Fibrillation, or all of them as a file.
02

Study summary

This is a clinical study investigating pharmacokinetics, pharmacodynamic effects and safety of BAY 59-7939 in patients with atrial fibrillation (originally described in Japanese).

03

Conditions studied

  • Atrial Fibrillation

Browse trials for

Keywords

  • Atrial Fibrillation
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 20 years or older
  • Japanese male or female
  • Non- valvular atrial fibrillation documented by
  • Patients aged 60 years and older or with a risk of stroke

Exclusion criteria

Exclusion Criteria:

  • Prior stroke and
  • Patients in whom anticoagulants are
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    Arm 1

    Drug: Rivaroxaban (BAY59-7939)

  • Experimental
    Arm 2

    Drug: Rivaroxaban (BAY59-7939)

Interventions

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics (PK) CL/f, AUC, Cmax, Pharmacodynamics (PD), Factor Xa activity, PT, PT-INR, aPTT and HEPTEST(R)

    Time frame: Day 14 and 28

Secondary outcomes

  1. Each category of bleeding events and adverse event

    Time frame: Throughout treatment and followup period

07

Study locations

12 sites
  • Kitakyushu, Fukuoka 800-0057, Japan
  • Kurume, Fukuoka 830-8577, Japan
  • Onga, Fukuoka 807-0051, Japan
  • Kitahiroshima, Hokkaido 061-1134, Japan
  • Amagasaki, Hyogo 660-8511, Japan
  • Kawachinagano, Osaka 586-8521, Japan
  • Suita, Osaka 565-0871, Japan
  • Fukuoka, 811-0213, Japan
  • Fukuoka, 814-0180, Japan
  • Osaka, 540-0006, Japan
  • Osaka, 553-0003, Japan
  • Osaka, 558-8558, Japan
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2004, a primary completion of Jun 2005 and a completion of Jun 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 17, 2008
First posted
Oct 24, 2008
Start
Jul 2004
Primary completionActual
Jun 2005
CompletionActual
Jun 2005
Last update
Dec 25, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 25, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00779064
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Oct 24, 2008
Start date
Jul 2004
Primary completion
Jun 2005
Completion
Jun 2005
Last update
Dec 25, 2014

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rivaroxaban

Start the discussion